Umberto Conte

1.2k total citations
27 papers, 360 citations indexed

About

Umberto Conte is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Umberto Conte has authored 27 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 12 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Umberto Conte's work include Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (7 papers) and Antifungal resistance and susceptibility (5 papers). Umberto Conte is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (7 papers) and Antifungal resistance and susceptibility (5 papers). Umberto Conte collaborates with scholars based in United States, France and Spain. Umberto Conte's co-authors include Yiyun Tang, Gregory A. Otterson, Liza C. Villaruz, Jared Weiss, Keith D. Wilner, Steven Ades, Sai‐Hong Ignatius Ou, Danielle Murphy, Jeffrey W. Clark and D. Ross Camidge and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Umberto Conte

23 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Umberto Conte United States	11	154	150	106	75	66	27	360
T. T. Wu United States	11	292 1.9×	138 0.9×	102 1.0×	31 0.4×	57 0.9×	13	596
Chang Ki Min South Korea	11	60 0.4×	163 1.1×	125 1.2×	31 0.4×	177 2.7×	38	416
Sara R. Rashkin United States	8	45 0.3×	88 0.6×	134 1.3×	36 0.5×	33 0.5×	16	379
Geoffroy Venton France	13	52 0.3×	116 0.8×	147 1.4×	59 0.8×	191 2.9×	53	497
Bruce Kressel United States	6	151 1.0×	130 0.9×	47 0.4×	31 0.4×	42 0.6×	9	298
Ernestina Tetteh United States	6	58 0.4×	91 0.6×	212 2.0×	70 0.9×	17 0.3×	6	343
Matilda Lee Singapore	9	66 0.4×	131 0.9×	91 0.9×	106 1.4×	11 0.2×	16	338
Kriti Mittal United States	9	136 0.9×	137 0.9×	159 1.5×	25 0.3×	13 0.2×	28	360
Tiffany Shih United States	5	30 0.2×	110 0.7×	106 1.0×	28 0.4×	20 0.3×	8	423
Lewis Au United Kingdom	11	81 0.5×	267 1.8×	88 0.8×	23 0.3×	7 0.1×	30	396

Countries citing papers authored by Umberto Conte

Since Specialization

Citations

This map shows the geographic impact of Umberto Conte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Umberto Conte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Umberto Conte more than expected).

Fields of papers citing papers by Umberto Conte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Umberto Conte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Umberto Conte. The network helps show where Umberto Conte may publish in the future.

Co-authorship network of co-authors of Umberto Conte

This figure shows the co-authorship network connecting the top 25 collaborators of Umberto Conte. A scholar is included among the top collaborators of Umberto Conte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Umberto Conte. Umberto Conte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elmeliegy, Mohamed, Andrea Viqueira, Erik Vandendries, et al.. (2025). Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma. Targeted Oncology. 20(2). 349–359. 2 indexed citations

Wang, Diane, et al.. (2025). Elranatamab Exposure–Safety Analysis in Relapsed or Refractory Multiple Myeloma. The Journal of Clinical Pharmacology. 66(1). e70130–e70130.

Prince, H. Miles, Nizar J. Bahlis, Paula Rodríguez‐Otero, et al.. (2024). MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 144(Supplement 1). 4738–4738. 5 indexed citations

Pianko, Matthew J., Charlotte Pawlyn, Shang‐Yi Huang, et al.. (2024). MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 4743–4743.

Bahlis, Nizar J., et al.. (2024). Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM‐3. British Journal of Haematology. 204(5). 1801–1810. 3 indexed citations

Sborov, Douglas W., Charlotte Pawlyn, Tadao Ishida, et al.. (2024). Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9.. Journal of Clinical Oncology. 42(16_suppl). 7522–7522. 1 indexed citations

Tomasson, Michael H., Shinsuke Iida, Rubén Niesvizky, et al.. (2024). Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study. HemaSphere. 8(7). 23 indexed citations

Mohty, Mohamad, Nizar J. Bahlis, Ajay K. Nooka, et al.. (2024). The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study. Blood. 144(Supplement 1). 1933–1933.

Bahlis, Nizar J., Ajay K. Nooka, Marco DiBonaventura, et al.. (2023). P-474 The effect of elranatamab on patient-reported outcomes in patients with relapsed/refractory multiple myeloma naïve and exposed to BCMA-directed therapies: results from the MagnetisMM-3 study. Clinical Lymphoma Myeloma & Leukemia. 23. S300–S301.

10.

Turner, Nicholas C., Alexander Laird, Melinda L. Telli, et al.. (2023). Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. npj Breast Cancer. 9(1). 81–81. 3 indexed citations

11.

Williams, Jason S., Diane Wang, David J. Gifondorwa, et al.. (2023). Elranatamab Exposure-Efficacy Analysis in Patients with Relapsed or Refractory Multiple Myeloma: Insights from Pooled Magnetismm Studies. Blood. 142(Supplement 1). 1995–1995. 1 indexed citations

12.

Touzeau, Cyrille, Nizar J. Bahlis, Christopher Maisel, et al.. (2023). P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3. HemaSphere. 7(S3). e16622f0–e16622f0. 3 indexed citations

13.

Raje, Noopur, Xavier Leleu, Alexander M. Lesokhin, et al.. (2023). MM-378 Efficacy and Safety of Elranatamab by Age and Frailty in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Subgroup Analysis From MagnetisMM-3. Clinical Lymphoma Myeloma & Leukemia. 23. S497–S497. 1 indexed citations

14.

Camidge, D. Ross, Gregory A. Otterson, Jeffrey W. Clark, et al.. (2021). Crizotinib in Patients With MET-Amplified NSCLC. Journal of Thoracic Oncology. 16(6). 1017–1029. 109 indexed citations

15.

Roilides, Emmanuel, Fabianne Carlesse, Margaret Tawadrous, et al.. (2020). Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia. The Pediatric Infectious Disease Journal. 39(4). 305–309. 18 indexed citations

16.

Hyman, David M., Amelia Zelnak, Todd M. Bauer, et al.. (2019). JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.. Journal of Clinical Oncology. 37(15_suppl). TPS2660–TPS2660. 11 indexed citations

17.

Turner, Nicholas C., Alexander Laird, H. S. Rugo, et al.. (2019). Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations. Annals of Oncology. 30. v108–v109. 1 indexed citations

18.

Camidge, D. Ross, Gregory A. Otterson, Jeffrey W. Clark, et al.. (2018). Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.. Journal of Clinical Oncology. 36(15_suppl). 9062–9062. 63 indexed citations

19.

Kullberg, Bart Jan, Piroon Mootsikapun, Márcio Nucci, et al.. (2017). Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. Journal of Antimicrobial Chemotherapy. 72(8). 2368–2377. 21 indexed citations

20.

Martin, Judith M., Mercedes Macías-Parra, Peter Múdrý, et al.. (2016). Safety, Efficacy, and Exposure–Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis. The Pediatric Infectious Disease Journal. 36(1). e1–e13. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact